Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low-Density Lipoprotein Cholesterol Level cannot be too Low: Considerations from Clinical Trials, Human Genetics, and Biology

29 Apr 2020

Abstract excerpt

LDL cholesterol is by far the best established "causal" cardiovascular risk. It is distributed normally, and the mean value ranges around 100~120 mg/dl. In terms of preventive cardiology, we now know very well that the lower the LDL cholesterol, the better. Clinical usefulness of aggressive LDL-lowering therapies using statin, ezetimibe, and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Lipids, and Metabolism
Share to Diabetes, Cardiovascular Risks, and Lipoproteins
Share to Lipoproteins and Cardiovascular Health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32350167
DOI: 10.5551/jat.rv17040

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Low-Density Lipoprotein Cholesterol Level cannot be too Low: Considerations from Clinical Trials, Human Genetics, and BiologyPMID 32350167Read ↗

Can LDL cholesterol be too low? Possible risks of extremely low levels.Semantic proximity Read ↗

Non-HDL cholesterol as a therapeutic goal.Semantic proximity Read ↗

Efficacy and safety of low levels of low-density lipoprotein cholesterol: trans-ancestry linear and non-linear Mendelian randomization analysesSemantic proximity Read ↗

How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors.Semantic proximity Read ↗

Lipoprotein(a): Bridging the Gap Between Screening and Treatment—A Narrative ReviewSemantic proximity Read ↗

Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes.Semantic proximity Read ↗

[Lowering of LDL cholesterol prevents cardiovascular diseases. "Normal values" are too high--treatment time is a crucial factor].Semantic proximity Read ↗

Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology.Semantic proximity Read ↗

Genetic Polymorphisms, LDL-C and sdLDL-C Help Optimize Coronary Heart Disease (CHD) TherapySemantic proximity Read ↗

Hyperalphalipoproteinemia and Beyond: The Role of HDL in Cardiovascular DiseasesSemantic proximity Read ↗

Inclisiran—Silencing the Cholesterol, Speaking up the PrognosisSemantic proximity Read ↗

Sex aspects in lipoprotein metabolism, dyslipidemia, and lipid-lowering therapy: A comprehensive reviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.